Logo image of ANGX

ANGEL STUDIOS INC (ANGX) Stock Fundamental Analysis

USA - NYSE:ANGX - US0349481095 - Common Stock

6.4 USD
+0.15 (+2.4%)
Last: 10/31/2025, 8:26:30 PM
6.39 USD
-0.01 (-0.16%)
After Hours: 10/31/2025, 8:26:30 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to ANGX. ANGX was compared to 80 industry peers in the Entertainment industry. ANGX may be in some trouble as it scores bad on both profitability and health. ANGX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ANGX had negative earnings in the past year.
ANGX Yearly Net Income VS EBIT VS OCF VS FCFANGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 0 5M -5M 10M 15M

1.2 Ratios

ANGX has a worse Return On Assets (-600.62%) than 96.25% of its industry peers.
Industry RankSector Rank
ROA -600.62%
ROE N/A
ROIC N/A
ROA(3y)-156.87%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ANGX Yearly ROA, ROE, ROICANGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ANGX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANGX Yearly Profit, Operating, Gross MarginsANGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

2

2. Health

2.1 Basic Checks

ANGX has less shares outstanding than it did 1 year ago.
The debt/assets ratio for ANGX is higher compared to a year ago.
ANGX Yearly Shares OutstandingANGX Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 5M 10M 15M 20M 25M
ANGX Yearly Total Debt VS Total AssetsANGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

An Altman-Z score of 29.53 indicates that ANGX is not in any danger for bankruptcy at the moment.
ANGX's Altman-Z score of 29.53 is amongst the best of the industry. ANGX outperforms 98.75% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 29.53
ROIC/WACCN/A
WACCN/A
ANGX Yearly LT Debt VS Equity VS FCFANGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

ANGX has a Current Ratio of 0.09. This is a bad value and indicates that ANGX is not financially healthy enough and could expect problems in meeting its short term obligations.
ANGX has a Current ratio of 0.09. This is amonst the worse of the industry: ANGX underperforms 93.75% of its industry peers.
A Quick Ratio of 0.09 indicates that ANGX may have some problems paying its short term obligations.
ANGX's Quick ratio of 0.09 is on the low side compared to the rest of the industry. ANGX is outperformed by 93.75% of its industry peers.
Industry RankSector Rank
Current Ratio 0.09
Quick Ratio 0.09
ANGX Yearly Current Assets VS Current LiabilitesANGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 1M 2M 3M 4M

More info and screens

1

3. Growth

3.1 Past

ANGX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -561.48%.
EPS 1Y (TTM)-561.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 11.79% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-123.53%
EPS Next 2Y0%
EPS Next 3Y11.79%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ANGX Yearly Revenue VS EstimatesANGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 100M 200M 300M
ANGX Yearly EPS VS EstimatesANGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ANGX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ANGX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANGX Price Earnings VS Forward Price EarningsANGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANGX Per share dataANGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.2 -0.4 -0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0%
EPS Next 3Y11.79%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ANGX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANGEL STUDIOS INC

NYSE:ANGX (10/31/2025, 8:26:30 PM)

After market: 6.39 -0.01 (-0.16%)

6.4

+0.15 (+2.4%)

Chartmill FA Rating
GICS IndustryGroupMedia & Entertainment
GICS IndustryEntertainment
Earnings (Last)N/A N/A
Earnings (Next)11-14 2025-11-14
Inst Owners0.15%
Inst Owner ChangeN/A
Ins Owners6.65%
Ins Owner Change0.08%
Market Cap1.08B
Revenue(TTM)N/A
Net Income(TTM)-5107100
AnalystsN/A
Price TargetN/A
Short Float %0.93%
Short Ratio0.38
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.69
EYN/A
EPS(NY)-0.69
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS-0.06
TBVpS-0.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -600.62%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-156.87%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.09
Quick Ratio 0.09
Altman-Z 29.53
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-561.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-123.53%
EPS Next 2Y0%
EPS Next 3Y11.79%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y4.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-141.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-141.22%
OCF growth 3YN/A
OCF growth 5YN/A

ANGEL STUDIOS INC / ANGX FAQ

What is the fundamental rating for ANGX stock?

ChartMill assigns a fundamental rating of 1 / 10 to ANGX.


What is the valuation status of ANGEL STUDIOS INC (ANGX) stock?

ChartMill assigns a valuation rating of 0 / 10 to ANGEL STUDIOS INC (ANGX). This can be considered as Overvalued.


What is the profitability of ANGX stock?

ANGEL STUDIOS INC (ANGX) has a profitability rating of 0 / 10.


How financially healthy is ANGEL STUDIOS INC?

The financial health rating of ANGEL STUDIOS INC (ANGX) is 2 / 10.